This site is intended for Healthcare professionals only.

Zydus Cadila gets USFDA nod to market breast cancer drug

Zydus Cadila gets USFDA nod to market breast cancer drug

New Delhi: Drug firm Zydus Cadila said it has received final approval from the United States Food and Drug Administration (USFDA) to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base).

It (Tamoxifen Citrate Tablets USP) will be manufactured at the group’s formulations manufacturing facility at SEZ in Ahmedabad, the company said in a BSE filing.

The drug is indicated to treat breast cancer, the company said in the filing.

The group now has more than 165 approvals, it added.

READ  USFDA rejects filing for Celgene MS drug, shares fall


Source: PTI
0 comment(s) on Zydus Cadila gets USFDA nod to market breast cancer drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted